1455 related articles for article (PubMed ID: 27256393)
1. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
3. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
4. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
7. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
[TBL] [Abstract][Full Text] [Related]
9. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
[TBL] [Abstract][Full Text] [Related]
11. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer.
Väyrynen SA; Zhang J; Yuan C; Väyrynen JP; Dias Costa A; Williams H; Morales-Oyarvide V; Lau MC; Rubinson DA; Dunne RF; Kozak MM; Wang W; Agostini-Vulaj D; Drage MG; Brais L; Reilly E; Rahma O; Clancy T; Wang J; Linehan DC; Aguirre AJ; Fuchs CS; Coussens LM; Chang DT; Koong AC; Hezel AF; Ogino S; Nowak JA; Wolpin BM
Clin Cancer Res; 2021 Feb; 27(4):1069-1081. PubMed ID: 33262135
[TBL] [Abstract][Full Text] [Related]
12. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
14. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Mahajan UM; Langhoff E; Goni E; Costello E; Greenhalf W; Halloran C; Ormanns S; Kruger S; Boeck S; Ribback S; Beyer G; Dombroswki F; Weiss FU; Neoptolemos JP; Werner J; D'Haese JG; Bazhin A; Peterhansl J; Pichlmeier S; Büchler MW; Kleeff J; Ganeh P; Sendler M; Palmer DH; Kohlmann T; Rad R; Regel I; Lerch MM; Mayerle J
Gastroenterology; 2018 Nov; 155(5):1625-1639.e2. PubMed ID: 30092175
[TBL] [Abstract][Full Text] [Related]
15. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
[TBL] [Abstract][Full Text] [Related]
16. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
19. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]